Sinovac wins successful bid for Turkyie vaccines

Chinese vaccine company Sinovac Biotech Ltd announced on Thursday that it has achieved a major milestone in international cooperation with its successful bid for Turkyie'slong-term supply project for hepatitis A and chickenpox vaccines.

The bid was won by KeyVacon May 24, a joint venture betweenSinovac and a Turkish partner, which hasa vaccine production base in Turkyiewith an annual capacity of 30 million doses.

Atestament to the strong collaboration between China and Turkyiein the public healthsector, the projectfollows years of efforts by Sinovacto supply vaccines to overseas markets.

The Turkish government, aiming to localize the production and supply of human vaccines, initiated an open tender programfor hepatitis A and chickenpox vaccines in December 2023. The tender officially opened on April 2, 2024, with KeyVacemerging as the successful bidder amidst fierce competition.

Yang Guang, chief business officer with Sinovac, said that the success of the project signifies a pivotal step for the company in advancing international cooperation and marks an important milestone for Chinese vaccine enterprises going global.

"The successful bid demonstrates that Sinovac's vaccine products, servicesand technological capabilities have earned the recognition and trust of Turkish government and people, to substantially fulfill the country'senduring vaccine demand," Yang said.

Sinovachas been actively involved in tendering for the supply of hepatitis A vaccines in Turkyiesince 2013 and has explored local production partnerships.

Since 2020, Sinovac has consistently supplied Turkyiewith COVID-19 vaccines, hepatitis A vaccines, influenza vaccines and chickenpox vaccines, with a cumulative total of nearly 94 million doses.

Sinovacand a local partner co-established KeyVacin 2021, investing $100 million on the production base of 29,500 square meters.